Following a recent poll, the VMD has refreshed the information provided in the monthly medicines update, please send any comments or feedback to postmaster@vmd.gov.uk. New marketing authorisations: See the VMD’s Product Information Database for more information. The authorisation territories, GB or NI, are links to their entry in the VMD’s Product Information Database. There may be a delay between the issuing of a Marketing Authorisation and the product being placed on the market. New Marketing

The pharmacovigilance team at the Veterinary Medicines Directorate (VMD) monitors adverse event reports for veterinary medicines authorised in the UK. We receive adverse event reports from vets, animal owners and Marketing Authorisation Holders (MAH). We have received lack of efficacy reports concerning the use of the euthanasia product - Somulose Solution for Injection (secobarbital and cinchocaine). We would therefore like to remind vets about the information contained in the Summary of Produc

New MAs and changes made and published to end of January 2021 The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions. Changes made to authorisations Repose 500 mg/ml solution for injection (Pentobarbital Sodium) (Le Vet Beheer B.V.) Authorised for cats, cattle, dogs, goats, horses, mink, pigs, rabbits, rodents, sheep Deletion of: 'In large animal species (horses, cattle, sheep, goats and pigs) lower do